User:Mr. Ibrahem/Tivozanib
{{#unlinkedwikibase:id=Q7810457}}
 | |
| Clinical data | |
|---|---|
| Trade names | Fotivda |
| Other names | AV-951 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | >99% |
| Elimination half-life | 4.5–5.1 days |
| Excretion | 79% faeces, 12% urine |
| Chemical and physical data | |
| Formula | C22H19ClN4O5 |
| Molar mass | 454.87 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tivozanib, sold under the brand name Fotivda, is a medication used to treat renal cell carcinoma (RCC).[1] Specifically it is used for advanced disease which has failed other treatments.[1] It is taken by mouth.[1]
Common side effects include tiredness, high blood pressure, diarrhea, nausea, change in voice, low thyroid, cough, and mouth inflammation.[1] Other side effects may include low sodium, heart problems, blood clots, bleeding, and increased lipase.[1] Use in pregnancy may harm the baby.[1] It is a VEGF receptor tyrosine kinase inhibitor, which blocks the formation of new blood vessels.[3][1]
Tivozanib was approved for medical use in Europe in 2017 and the United States in 2021.[3][1] In the United States 4 weeks of treatment costs about 26,000 USD.[4]
References[edit]
- ^ a b c d e f g h i j k "Fotivda- tivozanib capsule". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.
- ^ "FDA approves tivozanib for relapsed or refractory advanced renal cell". U.S. Food and Drug Administration. 10 March 2021. Archived from the original on 11 March 2021. Retrieved 16 March 2021.
This article incorporates text from this source, which is in the public domain.
- ^ a b c d "Fotivda EPAR". European Medicines Agency (EMA). Archived from the original on 13 May 2021. Retrieved 16 March 2021.
- ^ "Tivozanib". Archived from the original on 31 October 2022. Retrieved 31 October 2022.
